Outcomes Of Infant Acute Lymphoblastic Leukaemia; An Experience From Low Middle Income Country
DOI:
https://doi.org/10.36283/ziun-pjmd15-1/004Keywords:
Acute lymphoblastic leukaemia, Fever, Infants, Leukocytes, MortalityAbstract
Background: Acute Lymphoblastic Leukaemia (ALL) is the most common pediatric malignancy. This study was done to describe the prognostic factors and course of infant ALL in Pakistan.
Methods: This retrospective observational study was performed at the department of Paediatric Oncology/Haematology, CMH Hospital Rawalpindi, Pakistan, from January 2012 to December 2023. Data of infants with confirmed diagnosis of ALL by immunophenotyping and treated as per Interfant 06 protocol were analyzed. Non-probability consecutive sampling technique was adopted. Disease risk stratification was done based on clinical and laboratory markers. Prognostic factors, overall survival (OS), and disease-free survival (DFS) were documented. Statistical analysis was performed using IBM-SPSS Statistics, Version 26.0.
Results: In a total of 47 infants, there were 25 (53.2%) male, and the median age was 9.00 (6.00-10.00) months. Age (p<0.001), and MLL rearrangement (p<0.001) had significant association with disease risk group. During the evaluation period, relapse was noted among 17 (36.2%) cases. Mortality was reported among 33 (70.2%) cases. The median DFS, and OS were 6.90 (1.90-27.3) months, and 9.6 (2.90-29.0) months, respectively. ALL disease risk categorization was found to have significant association with overall survival (p=0.016). Evaluation of laboratory parameters revealed that mortality was significantly associated with higher leukocytes count (p=0.027), and lower platelets count (p=0.010).
Conclusion: The overall mortality in ALL is high. These findings highlight the critical role of risk group stratification, elevated WBC count, and low platelet count in predicting survival outcomes in infant ALL.
References
1. Ikramullah, Saleem S, Saad AB, Rehman N, Mufti MZ, Malik SN. Pediatric Acute Lymphoblastic Leukemia in Rawalpindi. J Pak Soc Intern Med. 2024 Jul-Sep;5(3): 635-639. doi: 10.70302/jpsim.v5i3.2455
2. Gözdaşoğlu S. Infant Leukemia. In: Li W, editor. Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 2. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586204/ doi: 10.36255/exon-publications-leukemia-infant-leukemia
3. Mansoor N, Imran S, Maqsood S, Pasha S, Jabbar N. Infantile B-lymphoblastic leukemia: a case series and review of the literature. J Int Med Res. 2023 Apr;51(4):3000605231167789. doi: 10.1177/03000605231167789
4. Mengxuan S, Fen Z, Runming J. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. Front Pediatr. 2022 Jun;10:923419. doi: 10.3389/fped.2022.923419
5. Farrag A, Ghazaly MH, Mohammed K, Volland R, Hero B, Berthold F. Comparing presentations and outcomes of children with cancer: a study between a lower-middle-income country and a high-income country. BMC Pediatr. 2023 Jan;23(1):443. doi: 10.1186/s12887-023-04214-8
6. Górecki M, Kozioł I, Kopystecka A, Budzyńska J, Zawitkowska J, Lejman M. Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. Biomedicines. 2023 Nov;11(3):821. doi: 10.3390/biomedicines11030821
7. Ibrahimova A, Winestone LE, Miller TP, Kettler K, Seif AE, Huang YS, et al. Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatr Blood Cancer. 2021 Jul;68(7):e28940. doi: 10.1002/pbc.28940
8. Ahmad I, Ghafoor T, Ullah A, Naz S, Tahir M, Ahmed S, et al. Pediatric Acute Lymphoblastic Leukemia: Clinical Characteristics, Treatment Outcomes, and Prognostic Factors: 10 Years' Experience From a Low- and Middle-Income Country. JCO Glob Oncol. 2023 June;9:e2200288. doi: 10.1200/GO.22.00288
9. Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019 Jun;66(6):e27620. doi: 10.1002/pbc.27620
10. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. Sep;2019;37(25):2246-2256. doi: 10.1200/JCO.19.00261
11. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):223-9. doi: 10.1016/j.bjhh.2015.03.009
12. Asees MY, Shrateh ON, Assi AS, Habbabeh M, Shiha HO, Shakhsheer S. Infantile B-cell acute lymphoblastic leukaemia with the highest recorded count of white blood cells in the literature: case report and literature review. Ann Med Surg (Lond). 2023 Dec;85(12):6294-6297. doi: 10.1097/MS9.0000000000001476
13. Huang FL, Liao EC, Li CL, Yen CY, Yu SJ. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments. Oncol Lett. 2020 Jul;20(1):448-454. doi: 10.3892/ol.2020.11583
14. Stutterheim J, Van der Sluis IM, Vrenken KS, Pieters R, Stam RW. KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges. Haematologica. 2025 Sep;110(9):1951-1961. doi: 10.3324/haematol.2024.285642
15. Guarnera L, D'Addona M, Bravo-Perez C, Visconte V. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int J Mol Sci. 2024 Aug;25(16):9023. doi: 10.3390/ijms25169023
16. Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30(5):1184-7. doi: 10.1038/leu.2015.246. Erratum in: Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279
17. Alghamdi AT, Alead JE, Darwish EG, Matasif ST, Qari MH. Prognostics and Clinical Outcomes in Patients Diagnosed With Acute Lymphoblastic Leukemia in King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Cureus. 2022 Mar;14(3):e22952. doi: 10.7759/cureus.22952
18. Dai Q, Zhang G, Yang H, Wang Y, Ye L, Peng L, et al. Clinical features and outcome of pediatric acute lymphoblastic leukemia with low peripheral blood blast cell count at diagnosis. Medicine (Baltimore). 2021 Jan;100(4):e24518. doi: 10.1097/MD.0000000000024518
19. Donadieu J, Auclerc MF, Baruchel A, Perel Y, Bordigoni P, Landman-Parker J, et al. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE). Br J Cancer. 2000 Dec;83(12):1617-22. doi: 10.1054/bjoc.2000.1504
20. Brum da Silva Nunes V, Kehl Dias C, Nathali Scholl J, Nedel Sant'Ana A, de Fraga Dias A, Granero Farias M, et al. Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification. Discov Oncol. 2022 Dec;13(1):143. doi: 10.1007/s12672-022-00602-1
21. Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. J Pediatr Hematol Oncol. 2001 Sep;23(9):591-7. doi: 10.1097/00043426-200112000-00008
22. Hayashi H, Makimoto A, Yuza Y. Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective. Cancers (Basel). 2024 Feb;16(4):723. doi: 10.3390/cancers16040723
23. Devarapalli UV, Sarma MS, Mathiyazhagan G. Gut and liver involvement in pediatric hematolymphoid malignancies. World J Gastrointest Oncol. 2022 Mar;14(3):587-606. doi: 10.4251/wjgo.v14.i3.587
24. Loganathan A, Bharadwaj R, Srinivasan A, Scott JX. Cytogenetics and Molecular Genetics in Pediatric Acute Lymphoblastic Leukemia (ALL) and Its Correlation with Induction Outcomes. South Asian J Cancer. 2022 Aug;11(4):353-360. doi: 10.1055/s-0042-1754337
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
